161 related articles for article (PubMed ID: 17057085)
21. Leishmaniasis host response loci (lmr1-3) modify disease severity through a Th1/Th2-independent pathway.
Elso CM; Roberts LJ; Smyth GK; Thomson RJ; Baldwin TM; Foote SJ; Handman E
Genes Immun; 2004 Mar; 5(2):93-100. PubMed ID: 14668789
[TBL] [Abstract][Full Text] [Related]
22. Critical role of dendritic cells in determining the Th1/Th2 balance upon Leishmania major infection.
Suzue K; Kobayashi S; Takeuchi T; Suzuki M; Koyasu S
Int Immunol; 2008 Mar; 20(3):337-43. PubMed ID: 18195051
[TBL] [Abstract][Full Text] [Related]
23. Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis.
Silveira FT; Lainson R; De Castro Gomes CM; Laurenti MD; Corbett CE
Parasite Immunol; 2009 Aug; 31(8):423-31. PubMed ID: 19646206
[TBL] [Abstract][Full Text] [Related]
24. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice.
Anderson CF; Mendez S; Sacks DL
J Immunol; 2005 Mar; 174(5):2934-41. PubMed ID: 15728505
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice.
Remer KA; Apetrei C; Schwarz T; Linden C; Moll H
Eur J Immunol; 2007 Sep; 37(9):2463-73. PubMed ID: 17705130
[TBL] [Abstract][Full Text] [Related]
26. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
Badiee A; Jaafari MR; Khamesipour A
Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of peritoneal macrophage phagocytic activity against Leishmania major by garlic (Allium sativum) treatment.
Ghazanfari T; Hassan ZM; Khamesipour A
J Ethnopharmacol; 2006 Feb; 103(3):333-7. PubMed ID: 16213117
[TBL] [Abstract][Full Text] [Related]
28. Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice.
Sacks D; Anderson C
Immunol Rev; 2004 Oct; 201():225-38. PubMed ID: 15361244
[TBL] [Abstract][Full Text] [Related]
29. Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent L. major.
Daneshvar H; Burchmore R; Hagan P; Phillips RS
Parasitology; 2009 Sep; 136(11):1243-50. PubMed ID: 19646303
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility to infectious diseases: Leishmania as a paradigm.
Locksley RM; Pingel S; Lacy D; Wakil AE; Bix M; Fowell DJ
J Infect Dis; 1999 Mar; 179 Suppl 2():S305-8. PubMed ID: 10081500
[TBL] [Abstract][Full Text] [Related]
31. BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responses.
Brunner C; Sindrilaru A; Girkontaite I; Fischer KD; Sunderkötter C; Wirth T
EMBO J; 2007 Jul; 26(13):3191-202. PubMed ID: 17568779
[TBL] [Abstract][Full Text] [Related]
32. Leishmania major CorA-like magnesium transporters play a critical role in parasite development and virulence.
Zhu Y; Davis A; Smith BJ; Curtis J; Handman E
Int J Parasitol; 2009 May; 39(6):713-23. PubMed ID: 19136005
[TBL] [Abstract][Full Text] [Related]
33. The role of mannose receptor during experimental leishmaniasis.
Akilov OE; Kasuboski RE; Carter CR; McDowell MA
J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547
[TBL] [Abstract][Full Text] [Related]
34. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
[TBL] [Abstract][Full Text] [Related]
35. Experimental cutaneous Leishmaniasis: a powerful model to study in vivo the mechanisms underlying genetic differences in Th subset differentiation.
Louis J; Gumy A; Voigt H; Röcken M; Launois P
Eur J Dermatol; 2002; 12(4):316-8. PubMed ID: 12095873
[TBL] [Abstract][Full Text] [Related]
36. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?
McMahon-Pratt D; Alexander J
Immunol Rev; 2004 Oct; 201():206-24. PubMed ID: 15361243
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
Nahrevanian H; Farahmand M; Aghighi Z; Assmar M; Amirkhani A
Exp Parasitol; 2007 Jul; 116(3):233-40. PubMed ID: 17335813
[TBL] [Abstract][Full Text] [Related]
38. Germ-free mice produce high levels of interferon-gamma in response to infection with Leishmania major but fail to heal lesions.
Oliveira MR; Tafuri WL; Afonso LC; Oliveira MA; Nicoli JR; Vieira EC; Scott P; Melo MN; Vieira LQ
Parasitology; 2005 Oct; 131(Pt 4):477-88. PubMed ID: 16174412
[TBL] [Abstract][Full Text] [Related]
39. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.
Scott P; Artis D; Uzonna J; Zaph C
Immunol Rev; 2004 Oct; 201():318-38. PubMed ID: 15361250
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response.
Kébaïer C; Louzir H; Chenik M; Ben Salah A; Dellagi K
Infect Immun; 2001 Aug; 69(8):4906-15. PubMed ID: 11447167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
